News Tiny Molecules in Blood Could Be Biomarkers of MS Progression, Study Says Tiny Molecules in Blood Could Be Biomarkers of MS Progression, Study Says by Joana Fernandes, PhD | January 27, 2017 Share this article: Share article via email Copy article link MicroRNAs in the blood could serve as biomarkers to monitor the progression of multiple sclerosis (MS), as well as help identify which mechanisms are at play in each patient, such as inflammation and tissue damage, according to new research. The findings were reported in the study, āAssociation Between Serum MicroRNAs and Magnetic Resonance Imaging Measures Of Multiple Sclerosis Severity.ā It was published in the journal JAMA Neurology. MicroRNAs are tiny RNA molecules that can control gene expression and regulate protein production. They have the ability to bind to an mRNA molecule (a copy of the coding information required to produce a protein) and block production of a given protein. MicroRNAs can bind to many different mRNA molecules, which makes them powerful regulators. Although microRNAs are produced within the cells, where they function, some can be secreted into several body fluids.Ā They are highly resistant to degradation, so circulating microRNAs could be ideal biomarkers to follow the progression of certain diseases. Karen Regev, MD, of Harvard Medical School, and her colleagues previouslyĀ demonstrated that MS patients had a specific set of microRNAs in theirĀ blood, and that those molecules could be biomarkers to diagnose the disease. Using magnetic resonance imaging (MRI), they’ve nowĀ found that those microRNAs are correlated with brain and spinal damage. Their study enrolled two groups of MS patients (41 in one group, 79 in the other), and researchers compared the microRNAs in the patientsā blood samples to the brain and spinal lesions detected in the MRIs. Results showed some microRNAs were protective (associated with less damage), while others were harmful and linked to brain and spinal cord injury. In addition, different microRNAs were associated with different damage locations. The team also found that specific microRNAs were associated with lesions or atrophy.Ā TheirĀ presence could help doctors identify which mechanisms are at play in each patient. “These findings tell us the disease is heterogeneous,ā Rohit Bakshi, MD, MA, one of the study’s senior authors, said in a news release. āThere’s a complex set of mechanisms at play, and it may vary from patient to patient.” “Another implication of this research is that it could eventually lead to us having a blood test to identify the subtype of MS in a patient, to help guide therapeutic decisions and prognosis,” he added. Researchers emphasizedĀ that more studies are necessary to validate their results. “MicroRNAs could serve as biomarkers of the underlying MS disease processes, once validated and standardized for clinical settings,ā said Roopali Gandhi, PhD, the study’s other senior author. āIn addition, these markers have the potential to provide novel treatment targets.” Print This Page About the Author Joana Fernandes, PhD Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology. Tags biomarkers, brain, disease progression, inflammation, microRNAs, spinal cord
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression
April 25, 2024 News by Margarida Maia, PhD Having MS may marginally increase likelihood of cervical cancer: Study
April 25, 2024 News by Marisa Wexler, MS MS patients prefer Tysabri injection to intravenous infusion: Study